EPIGENOMICS AG Financials Epigenomics AG Deutsche Boerse AG
Equities
ECX
DE000A11QW50
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.785 EUR | -1.92% |
|
+9.51% | -4.03% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 59.42 | 20.03 | 7.841 | 6.958 | 1.613 | 1.417 | - | - |
| Enterprise Value (EV) 1 | 48.38 | 16.19 | -15.21 | -3.168 | 1.613 | -0.7212 | -0.2762 | 1.417 |
| P/E ratio | -2.97 x | -1.68 x | -2.91 x | -0.57 x | - | -2.4 x | -2.42 x | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 52.8 x | 23.8 x | 1.26 x | 14.3 x | 4.75 x | 9.45 x | - | - |
| EV / Revenue | 43 x | 19.3 x | -2.45 x | -6.53 x | 4.75 x | -4.81 x | - | - |
| EV / EBITDA | -3.42 x | -1.46 x | 7.86 x | 0.28 x | -0.3 x | -1.8 x | -1.38 x | - |
| EV / FCF | -3.56 x | -1.69 x | 3.63 x | 0.25 x | - | -1.03 x | -2.76 x | - |
| FCF Yield | -28.1% | -59.2% | 27.5% | 406% | - | -97.1% | -36.2% | - |
| Price to Book | 5.28 x | 5.18 x | 0.45 x | 0.68 x | - | 0.37 x | 0.45 x | - |
| Nbr of stocks (in thousands) | 272 | 295 | 612 | 819 | 853 | 880 | - | - |
| Reference price 2 | 218.4 | 68.00 | 12.82 | 8.500 | 1.890 | 1.610 | 1.610 | 1.610 |
| Announcement Date | 4/29/20 | 3/25/21 | 3/24/22 | 4/28/23 | 3/15/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.125 | 0.84 | 6.203 | 0.485 | 0.3392 | 0.15 | - | - |
| EBITDA 1 | -14.16 | -11.09 | -1.935 | -11.3 | -5.298 | 0.4 | 0.2 | - |
| EBIT 1 | -14.67 | -11.63 | -2.354 | -12.05 | -6.095 | -0.54 | -0.55 | - |
| Operating Margin | -1,304.27% | -1,384.17% | -37.95% | -2,484.54% | -1,796.7% | -360% | - | - |
| Earnings before Tax (EBT) 1 | -14.57 | -11.66 | -2.41 | -12.1 | -4.464 | -0.59 | -0.6 | - |
| Net income 1 | -17.02 | -11.7 | -2.428 | -12.02 | -4.464 | -0.59 | -0.6 | - |
| Net margin | -1,512.89% | -1,392.86% | -39.14% | -2,479.18% | -1,315.78% | -393.33% | - | - |
| EPS 2 | -73.60 | -40.40 | -4.400 | -14.80 | - | -0.6709 | -0.6658 | - |
| Free Cash Flow 1 | -13.58 | -9.581 | -4.187 | -12.87 | - | 0.7 | 0.1 | - |
| FCF margin | -1,207.2% | -1,140.6% | -67.5% | -2,653.81% | - | 466.67% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | 175% | 50% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 4/29/20 | 3/25/21 | 3/24/22 | 4/28/23 | 3/15/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 11 | 3.84 | 23 | 10.1 | - | 2.14 | 1.69 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -13.6 | -9.58 | -4.19 | -12.9 | - | 0.7 | 0.1 | - |
| ROE (net income / shareholders' equity) | -121% | -173% | -18.7% | -74.5% | - | -10% | -19.2% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 41.30 | 13.10 | 28.50 | 12.40 | - | 4.300 | 3.600 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.08 | 0.01 | 0.04 | 0.85 | - | - | - | - |
| Capex / Sales | 6.67% | 1.19% | 0.56% | 174.64% | - | - | - | - |
| Announcement Date | 4/29/20 | 3/25/21 | 3/24/22 | 4/28/23 | 3/15/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.61
EUR
Average target price
16.85
EUR
Spread / Average Target
+946.58%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 377M |
- Stock Market
- Equities
- ECX Stock
- ECX Stock
- Financials Epigenomics AG
